Gutsy Learning Series

The Gutsy Learning Series provides unparalleled access to Canada's top IBD researchers and healthcare providers! This is a special opportunity to connect directly with leaders in the field and strengthen your knowledge of Crohn's disease and colitis.

Available online and in-person, the series is accessible across Canada. All of our talks are recorded for future viewing on our Gutsy Learning Videos page. Due to the COVID-19 pandemic, all of our 2020-21 Gutsy Learning Series events will virtual untill further notice. 

Registrants have the opportunity to get their questions answered by the experts during an interactive, live Q&A period. Questions can be asked ahead of time during registration or the live broadcast. Can't join us live, register for webinar(s) and we will send you a link to the recording!

Scroll down the page for our list of upcoming events, or click here to watch past events. 

Upcoming events

Biologic and Biosimilar Medications for IBD

Event Details

Date: February 11, 2021
Time: 7:00 - 8:30 pm ET

Join us to learn from expert gastroenterologists about biologic and biosimilar medications for the treatment of Crohn's or colitis. You will have the opportunity to ask your questions to the experts ahead of time when you register for the webinar or during the live broadcast. This webinar will be offered in English with live French translation.

Speakers

Dr. Paul Moayyedi (MD, PhD, MPH, FRCPC) is a Professor of Medicine and Past Director of the Division of Gastroenterology at McMaster University. He holds the Audrey Campbell Chair of Ulcerative Colitis Research and is currently the Assistant Dean of Research at McMaster University. He has published over 425 peer-reviewed articles that have been cited over 56,000 times. He was Co-Editor in Chief of the American Journal of Gastroenterology 2010-2015. 

He is currently the joint Coordinating Editor of the Gut Cochrane Review Group and was co-author of the joint Canadian Association of Gastroenterology and Crohn's Colitis Canada position statement on biosimilars. He is a Principal Investigator of the IMAGINE Network Studies supported by Crohn's and Colitis Canada. 

Dr. Remo Panaccione (MD, FRCPC) is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary. He is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and has been recently recognized as a 2020 Clarivate Research Scholar for being cited in the top 1% of researchers cited in the world. He is the author of over 300 peer-reviewed articles including publications in journals such as the New England Journal of Medicine, Lancet, JAMA, Nature, and Annals of Internal Medicine. 

His special interest include advanced therapies, biological therapy, and delivery of care. He is a recognized authority on IBD therapeutics and has co-authored numerous guidelines for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn's disease and ulcerative colitis.

How to Register

Please click here to register for our next webinar. Can't join us live? Register to get a link to the recording. This webinar will be offered in English with live French translation.

Past events and videos

All of our GLS talks are recorded for future viewing. Please click here to watch past events on our Gutsy Learning Videos page.  

Need Help or Have questions?

For more information and support, please complete the form below or email us at learn@crohnsandcolitis.ca.

Our support staff will reply to your inquiry within 2 buisness days.

Enter security code:
 Security code

The Gutsy Learning Series presentations could not occur without the support of our generous sponsors:

GLS-Virtual-Sponsor-logo-Aug-26.png

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest